» Articles » PMID: 38601669

Identification of Cuproptosis-related MiRNAs in Triple-negative Breast Cancer and Analysis of the MiRNA-mRNA Regulatory Network

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Apr 11
PMID 38601669
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The close association between cuproptosis and tumor immunity in triple-negative breast cancer (TNBC) allows its monitoring for predicting the prognosis of patients with TNBC. Nevertheless, the biological function and prognostic value of cuproptosis-related miRNAs and their target genes have not been reported.

Purpose: To construct the miRNA and mRNA-based risk models associated with cuproptosis for patients with TNBC.

Methods: Comparison of expression levels for genes associated with cuproptosis was executed between patients in the normal individuals and the TCGA-TNBC cohort. Conducting differential analysis resulted in the identification of differentially expressed miRNA (DE-miRNAs) and differentially expressed genes (DEGs) between the TNBC and Control samples. Screening for prognostic miRNAs and biomarkers involved employing univariate Cox analysis and least absolute shrinkage and selection operator regression analyses. These methods were utilized to construct risk models aimed at predicting the survival of patients with TNBC. Based on the median value of risk scores, patients were then stratified into low- and high-risk groups. Functional enrichment analysis was employed to explore the potential function and pathways of prognostic genes. Additionally, independent prognostic analysis was performed through univariate and multivariate Cox regression. Immune infiltration analysis was performed to examine disparities in the infiltration of immune cells between the two risk groups. Finally, the prognostic gene expression was mined in key cell types of TNBC.

Results: We obtained 5213 DEGs and 204 DE-miRNAs related to cuproptosis between TNBC and Control samples. Five prognostic miRNAs (miR-203a-3p, miR-1277-3p, miR-135b-5p, miR-200c-3p, and miR-592) and three biomarkers (DENND5B, IGF1R, and MEF2C) were closely associated with TNBC. Significant differences in the functions of prognostic genes between the two risk groups were observed, encompassing adipogenesis, inflammatory response, and hormone metabolic process. The prognostic gene regulatory network revealed that miR200C-3p regulated ZFPM2 and CFL2, and miR-1277-3p regulated BMP2 and RORA. A nomogram was created based on riskScore, cancer status, and pathologic stage to predict 1/3/5-year survival of patients with TNBC. Immune infiltration analysis indicated that the immune microenvironment may be associated with the progression of TNBC. Interestingly, prognostic genes exhibited higher expression levels in T cells, fibroblasts, endothelial cells, and monocytes compared to other cells.

Conclusions: Five prognostic miRNA (miR-203a-3p, miR-1277-3p, miR-135b-5p, miR-200c-3p, and miR-592) and three biomarkers (DENND5B, IGF1R, and MEF2C) were significantly associated with TNBC, it provides new therapeutic targets for the treatment and prognosis of TNBC.

Citing Articles

ATP7A as a prognostic biomarker and potential therapeutic target in gastric cancer.

Shi Z, Mao Z, Cui M, Xu D, Wang Y, Jing R Am J Transl Res. 2025; 17(1):512-527.

PMID: 39959193 PMC: 11826209. DOI: 10.62347/UYMP7222.


Unraveling non-coding RNAs in breast cancer: mechanistic insights and therapeutic potential.

Shaikh M, Doshi G Med Oncol. 2024; 42(1):37.

PMID: 39730979 DOI: 10.1007/s12032-024-02589-x.


Elucidating the evolving role of cuproptosis in breast cancer progression.

Zhu Z, Zhu K, Zhang J, Zhou Y, Zhang Q Int J Biol Sci. 2024; 20(12):4872-4887.

PMID: 39309446 PMC: 11414396. DOI: 10.7150/ijbs.98806.


MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3.

Peng C, Li X, Yao Y, Nie Y, Fan L, Zhu C Cancer Biol Ther. 2024; 25(1):2373497.

PMID: 38967961 PMC: 11229718. DOI: 10.1080/15384047.2024.2373497.

References
1.
Li J, Qiao H, Wu F, Sun S, Feng C, Li C . A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses. Front Immunol. 2022; 13:998140. PMC: 9585224. DOI: 10.3389/fimmu.2022.998140. View

2.
Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R . Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics. 2022; 12(11):4965-4979. PMC: 9274752. DOI: 10.7150/thno.73152. View

3.
Chen L, Zhang Z, Yi Z, Li J . MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1. Br J Cancer. 2017; 117(1):78-88. PMC: 5520212. DOI: 10.1038/bjc.2017.150. View

4.
Li J, Goh E, He J, Li Y, Fan Z, Yu Z . Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer. Biology (Basel). 2023; 12(5). PMC: 10215321. DOI: 10.3390/biology12050697. View

5.
Zhang D, Li Y, Xu Y, Kim J, Huang S . Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth. Oncogene. 2018; 38(7):1106-1120. PMC: 7362578. DOI: 10.1038/s41388-018-0499-2. View